Bionano Genomics (BNGO) awards 15,000 stock options to its COO
Rhea-AI Filing Summary
OLDAKOWSKI MARK reported acquisition or exercise transactions in this Form 4 filing.
Bionano Genomics reported a Form 4 for Chief Operating Officer Mark Oldakowski showing a grant of 15,000 stock options to buy common stock at $1.12 per share, expiring in 2036. The options vest 50% on each of the first two anniversaries of the vesting commencement date, subject to continuous service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
OLDAKOWSKI MARK
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 shares (Direct)
Footnotes (2)
- F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
- F2. The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.
Key Figures
Stock options granted: 15000.0000 shares
Exercise price: $1.1200 per share
Underlying common shares: 15000.0000 shares
+2 more
5 metrics
Stock options granted
15000.0000 shares
Number of stock options granted to COO Mark Oldakowski on 2026-08-03
Exercise price
$1.1200 per share
Conversion or exercise price of the granted stock options
Underlying common shares
15000.0000 shares
Shares of common stock underlying the granted stock options
Options after transaction
15000.0000 shares
Total derivative securities held following the reported grant
Option expiration date
2036-08-02
Expiration date of the granted stock options
Key Terms
Stock Option (Right to Buy), Continuous Service, vesting commencement date, 2018 Plan
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Continuous Service financial
"subject to the Reporting Person's Continuous Service under the 2018 Plan"
vesting commencement date financial
"vest 50% of the total on each of the first and second anniversaries of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
2018 Plan financial
"as defined in the Company's 2018 Plan through each applicable vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Bionano Genomics (BNGO) report for Mark Oldakowski?
COO Mark Oldakowski received a grant of 15,000 stock options to purchase Bionano Genomics common stock. The options were awarded at a $1.12 exercise price per share and are reported as a derivative acquisition on a Form 4 insider report.
How many stock options did the BNGO COO receive and at what exercise price?
Mark Oldakowski received 15,000 stock options with an exercise (conversion) price of $1.12 per share. Each option relates to one share of Bionano Genomics common stock, giving him the right to buy up to 15,000 shares at that price.
What are the vesting terms of the 15,000 BNGO stock options granted to the COO?
The options vest 50% on each of the first and second anniversaries of the vesting commencement date. Vesting is conditioned on the reporting person’s Continuous Service under Bionano Genomics’ 2018 Plan through each applicable vesting date.
When do the newly granted BNGO stock options to the COO expire?
The stock options granted to Mark Oldakowski expire on 2036-08-02. After that expiration date, any unexercised options will no longer be exercisable, so the right to buy Bionano Genomics common shares at $1.12 per share will lapse.
Does the Form 4 for BNGO indicate the use of a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, meaning the reported grant is not designated as made pursuant to a Rule 10b5-1 trading plan. It is reported simply as a grant or award acquisition of derivative securities.
How does this Form 4 relate to the earlier Form 3 for Bionano Genomics (BNGO)?
A footnote states that the initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces that Form 3, serving as the corrected insider ownership and transaction report for Mark Oldakowski’s option grant.